Intellia Therapeutics Acquires Rewrite Therapeutics
The acquisition is, indeed good news.
By acquiring Rewrite Therapeutics, Intellia Therapeutics (NTLA) has inherited a versatile DNA writing platform which enables a range of innovative genome editing strategies. The acquisition is expected to further expand Intellia’s industry-leading genome editing toolbox by adding a highly complementary platform to its existing CRISPR/Cas9 and . . .
This content is for paid subscribers.
Impacting News February 7, 2022